By 2030, the number of people aged 60 years and older is expected to increase by more than a third, to 1.4 billion. Adult immunization is one of the most cost-effective public health preventative interventions available, accruing returns on investment at the individual, healthcare system, economic, societal, and political levels. However, despite the clear benefits, vaccination coverage is almost always much lower in adults than in pediatric vaccination programs. Maximizing the uptake of vaccines among the adult population is critical for reducing disease-associated outcomes and leads to improved health and reduced healthcare costs.
This research brief from the IQVIA Institute – Trends in Global Adult Vaccination: Impact of COVID-19 – aims to provide a baseline of adult vaccination trends and missed vaccination doses during the COVID-19 pandemic while assessing variations by countries and regions.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Leverage numerous infectious disease and vaccine experts using best-in-class data sources and the right sites.
